San Diego-primarily based Viking Therapeutics marked alone as a significant competitor during the weight loss drug sector in February immediately after revealing promising facts from a mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when specified as being a weekly injection and in Marc